Skip to main content
. 2020 Nov 14;102:319–326. doi: 10.1016/j.ijid.2020.11.145

Table 3.

Characteristics of Patients through meta analysis.

Variable Total Patients(n) Average 95% CI I2% P value
Clinical Characteristics
Age (years) 147 8.99 7.99-9.98 <0.01 0.92
Gastrointestinal symptoms (n%) 182 0.9 0.71-1 87.62 <0.01
Febrile and inflammatory (n%) 182 0.8 0.44-1 95.75 <0.01
Shock (n%) 182 0.74 0.57-.088 80.03 <0.01
left ventricular dysfunction (n%) 182 0.70 0.44-.091 91.19 <0.01
KD (n%) 182 0.17 0.02-0.40 90.92 <0.01
respiratory symptom (n%) 182 0.09 0-0.29 91.08 <0.01
Risk factors and Laboratory Results
Contact with Viral (n%) 182 0.15 0.01-0.40 92.02 <0.01
Onset of Kawa-COVID-19 to hospitalization (days) 71 5.9 5.55-6.25 31.30 0.23
Nucleic acid positive of SARS Cov-2 (n%) 182 0.37 0.26-0.50 59.94 <0.01
lgG of SARS Cov-2 (n%) 182 0.81 0.74-0.86 34.25 0.17
Lymphocyte (*10^9/l) 98 0.92 0.74-1.11 6 0.36
Platelet (*10^9/l) 132 166.84 150.54-183.14 75.30 03
CRP (mg/l) 182 210.80 183-238.59 47.40 0.08
IL-6 (pg/ml) 49 138.63 103.78-173.48 <0.01 0.71
PCT (ng/ml) 80 35.51 10.64-60.37 <0.01 0.99
Albumin (g/l) 125 21.96 20.01-23.91 65.40 0.02
Troponin (ng/l) 180 60.21 21.88-95.54 15.70 0.31
NT-proBNP (pg/ml) 141 6526.48 1142.31-11910.66 95.20 <0.01
D-dimer (ng/ml) 124 3588.13 1968.50-5207.77 76.80 <0.01
Treatments
Intravenous immunoglobulin (n%) 182 0.9 0.76-0.99 82.85 <0.01
Anticoagulation (n%) 87 0.77 0.48-0.97 85.78 <0.01
Inotropic support (n%) 182 0.67 0.51-0.82 78.46 <0.01
Intubation (n%) 182 0.33 0.13-0.57 89.34 <0.01
Corticosteroids (n%) 182 0.35 0.21-0.51 76.54 <0.01
Outcome
Length of hospital stay (days) 99 10.66 8.86-12.46 61.30 0.03
Admitted to intensive care unit (n%) 182 0.74 0.52-0.91 88.13 <0.01
Dilatation of the coronary arteries (n%) 182 0.17 0.09-0.28 61.40 0.02
Acute kidney injury (n%). 182 0.13 0-0.37 91.97 <0.01